Kentucky Medicaid and GLP-1 coverage

Kentucky's drug list has no anti-obesity section. Wegovy, Zepbound, Saxenda, Contrave, Qsymia, Imcivree, phentermine and orlistat are not on it anywhere, and neither are the words "obesity" or "weight loss" — though insulin appears 15 times and glucagon 3, so they are absent from the list rather than from our reading of it. The edition reads "August 2026" on its face.

Kentucky Medicaid, Preferred Drug List, effective August 2026 · source

The GLP-1 class Kentucky does have is a diabetes class. Under the heading "GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS" the list carries Mounjaro pen, Ozempic pen, Trulicity pen and Victoza pen as preferred, with exenatide pen, liraglutide pen, Ozempic tablet, Rybelsus tablet, Soliqua pen and Xultophy pen non-preferred. Neither Wegovy nor Zepbound is in it.

Kentucky Medicaid, Preferred Drug List, effective August 2026 · source

Wegovy has two routes, and the heart-risk one wants proof you were already on the standard heart drugs first. Initial approval requires "Patient age ≥ 45 years", that it is "Being prescribed for MACE risk reduction (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke)", documented pre-existing cardiovascular disease, and "a claims history showing optimization on specified lipid-lowering therapy (e.g., moderate to high intensity statin, PCSK9)" plus a beta-blocker, a RAS inhibitor or an antiplatelet — or a stated medical reason why none can be used. The patient must also have "a body-mass index (BMI) of 27 kg/m2 or greater". Approval runs 6 months. The second route is liver disease: the same criteria open "For Metabolic Dysfunction-Associated Steatohepatitis (MASH)" for patients 18 or older with "moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)", and the request may not be for the Wegovy tablet.

Kentucky Medicaid, Prior Authorization Criteria — Wegovy (semaglutide) · source

Zepbound turns partly on a diagnosis you must NOT have. It requires "Prescribed by or in consultation with a neurologist, sleep specialist, or other specialist in the treatment of OSA" and a "≥ 3-month trial and failure, contraindication, or intolerance" of APAP, BiPAP or CPAP therapy, with a BMI of 30 or greater. It then requires that the "Patient does NOT have any of the following: i. A history of diabetes; ii. Current A1c of 6.5% or higher". Age limit 18 and up; approval 6 months.

Kentucky Medicaid, Prior Authorization Criteria — Zepbound (tirzepatide) · source

Your plan does not change the answer, because state law says it cannot. KRS 205.5514 requires that the department "Establish a single preferred drug list to be used by the state pharmacy benefit manager for each managed care organization with whom the department contracts for the delivery of Medicaid services".

Kentucky Revised Statutes 205.5514, Department's duties regarding state pharmacy benefit management, effective March 2020 · source

If the state denied you, the clock is short and measured by postmark. The fee-for-service rule requires that a hearing request "Be postmarked within thirty (30) calendar days from the date of the department's written notice".

907 KAR 1:563, Fee-for-service hearings and appeals · source

If a managed care plan denied you, two longer clocks run in sequence. "An enrollee shall have sixty (60) calendar days from the date of receiving a notice of adverse action from an MCO to file an appeal either orally or in writing with the MCO", and a later state fair hearing request must "Be postmarked or filed within 120 calendar days from the date of the MCO adverse action letter issued at the conclusion of the MCO internal appeal process".

907 KAR 17:010, Managed care organization appeals and state fair hearings · source